人工智能检测转甲状腺素蛋白心脏淀粉样变:一项非随机临床试验
本研究开发并评估了人工智能增强的ATTR-CM检测项目ATTRACTnet,模型基于心电图波形、超声心动图测量、人口学特征及淀粉样变骨科表现诊断代码构建。在单系统多中心单臂开放标签试验中,筛查出1471例AI评分≥0.5的患者,其中256例符合标准,50例接受检测,24例(48%)确诊ATTR-CM,21例(88%)在3个月内启动治疗。
要点
- AI筛查阳性且符合标准的患者中,48%(24/50)确诊ATTR-CM,88%(21/24)在3个月内启动治疗。
核心结论
- AI增强筛查可能提高ATTR-CM的检出率,并识别常规诊疗遗漏的患者。
- 需要前瞻性随机试验来确定是否能改善结局。
研究设计与样本
- 非随机临床试验,构建AI模型ATTRACTnet,使用心电图波形、超声心动图测量、人口学特征及淀粉样变骨科表现诊断代码。
- 模型在大型学术转诊中心训练和验证,并在另一学术中心外部验证。
- 单系统、多中心、单臂、开放标签试验评估真实世界性能;纳入左心室壁厚度≥12 mm且ATTRACTnet评分≥0.5的患者。
主要发现
- 内部测试集799例(平均年龄75.1岁,SD 11.1;男性516例[64.7%],女性283例[35.3%]),5折交叉验证AUC 0.85(范围0.77-0.85)。
- 研究期间识别1471例AI评分≥0.5的患者,256例符合标准,50例经医患同意后接受淀粉样变检测。
- 50例中24例(48%)确诊ATTR-CM,21例(88%)在3个月内启动治疗。
关键数值与推荐
- 纳入标准:左心室壁厚度≥12 mm且ATTRACTnet评分≥0.5。
- 排除标准:既往ATTR-CM检测、肥厚型心肌病、预期寿命<1年、养老院居住、晚期痴呆,或左心室壁厚度<14 mm且由未控制高血压或中/重度主动脉瓣狭窄解释。
- 主要结局:按共识标准诊断ATTR-CM。
临床怎么用
- 对于左心室壁厚度≥12 mm且AI评分≥0.5的患者,可考虑通知并提供核素闪烁显像、单克隆蛋白检测及随访护理。
- AI辅助筛查有助于发现常规诊疗可能遗漏的ATTR-CM患者。
局限性
- 为非随机单臂试验,需前瞻性随机试验确认是否改善结局。
- 符合标准的256例中仅50例实际接受检测,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is underdiagnosed despite expanding treatment options. OBJECTIVE: To develop and evaluate an artificial intelligence (AI)-augmented clinical program for ATTR-CM detection. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial involved constructing an AI model, ATTRACTnet, using electrocardiogram waveforms, echocardiographic measurements, demographics, and diagnosis codes for orthopedic manifestations of amyloidosis. A single-system, multisite, single-arm, open-label trial was conducted to evaluate its real-world performance. The model was trained and validated at a large academic referral site for ATTR-CM with external validation at an academic site. The trial was conducted as a single-system, multisite trial. Patients with left ventricular (LV) wall thickness 12 mm or more and an ATTRACTnet score 0.5 or higher were eligible. Exclusions included prior ATTR-CM testing, hypertrophic cardiomyopathy, expected life span less than 1 year, nursing home residence, advanced dementia, or LV wall thickness less than 14 mm explained by uncontrolled hypertension or moderate/severe aortic stenosis. INTERVENTION: Eligible patients were notified and offered nuclear scintigraphy testing, monoclonal protein testing, and follow-up care on agreement from the treating physician. MAIN OUTCOMES AND MEASURE: The primary outcome was a diagnosis of ATTR-CM by consensus criteria. ATTR-CM testing positivity was compared with historical and contemporary controls. RESULTS: ATTRACTnet was developed in an internal test set of 799 patients (mean [SD] age, 75.1 [11.1] years; 516 [64.7%] male and 283 [35.3%] female) using 5-fold cross-validation with an additional external test set of 422 patients. It had good discrimination for ATTR-CM detection with an area under the receiver operator characteristic curve of 0.85 (5-fold cross-validation, 0.77-0.85) in the internal set and 0.82 (95% CI, .81-0.83) in the external test set with similar performance in Hispanic, non-Hispanic Black, and non-Hispanic White patients. A total of 1471 patients were identified with positive AI model scores 0.5 or more during the study period, with 256 eligible patients who met study criteria. Of these patients, 50 underwent amyloidosis testing after physician and patient approval; 24 (48%) were diagnosed with ATTR-CM, and 21 (88%) initiated treatment within 3 months. The positivity rate was more than 2.8 times higher than historical controls (15.3%; 95% CI, 13.1%-17.9%; P < .001), with an 18% relative increase in new diagnoses vs the prior year. CONCLUSIONS AND RELEVANCE: AI-augmented screening may improve ATTR-CM detection and identify patients who are missed by usual care. Prospective randomized trials are needed to determine if outcomes are improved. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06469372.
引用
- Jain SS, Sun T, Pierson E, et al. Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41213043. doi:10.1001/jamacardio.2025.4591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。